Adversity Considerations for Thyroid Follicular Cell Hypertrophy and Hyperplasia in Nonclinical Toxicity Studies: Results From the 6th ESTP International Expert Workshop.

Huisinga M, Bertrand L, Chamanza R, Damiani I, Engelhardt J, Francke S, Freyberger A, Harada T, Harleman J, Kaufmann W, Keane K, KĂśhrle J, Lenz B, Marty MS, Melching-Kollmuss S, Palazzi X, Pohlmeyer-Esch G, Popp A, Rosol TJ, Strauss V, Van den Brink-Knol H, Wood CE, Yoshida M

A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials.

Raspa M, Bann CM, Gwaltney A, Benke TA, Fu C, Glaze DG, Haas R, Heydemann P, Jones M, Kaufmann WE, Lieberman D, Marsh E, Peters S, Ryther R, Standridge S, Skinner SA, Percy AK, Neul JL

Proliferative and Nonproliferative Lesions of the Rat and Mouse Central and Peripheral Nervous Systems: New and Revised INHAND Terms.

Bradley AE, Bolon B, Butt MT, Cramer SD, Czasch S, Garman RH, George C, GrĂśters S, Kaufmann W, Kovi RC, Krinke G, Little PB, Narama I, Rao DB, Sharma AK, Shibutani M, Sills R

Assessment of a Clinical Trial Metric for Rett Syndrome: Critical Analysis of the Rett Syndrome Behaviour Questionnaire.

Oberman LM, Downs J, Cianfaglione R, Leonard H, Kaufmann WE

A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments.

Budimirovic DB, Schlageter A, Filipovic-Sadic S, Protic DD, Bram E, Mahone EM, Nicholson K, Culp K, Javanmardi K, Kemppainen J, Hadd A, Sharp K, Adayev T, LaFauci G, Dobkin C, Zhou L, Brown WT, Berry-Kravis E, Kaufmann WE, Latham GJ

Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis.

Luu S, Province H, Berry-Kravis E, Hagerman R, Hessl D, Vaidya D, Lozano R, Rosselot H, Erickson C, Kaufmann WE, Budimirovic DB

Improving the Diagnosis of Autism Spectrum Disorder in Fragile X Syndrome by Adapting the Social Communication Questionnaire and the Social Responsiveness Scale-2.

Kidd SA, Berry-Kravis E, Choo TH, Chen C, Esler A, Hoffmann A, Andrews HF, Kaufmann WE

Experimental toolbox for quantitative evaluation of clathrin-mediated endocytosis in the plant model Arabidopsis.

Johnson A, Gnyliukh N, Kaufmann WA, Narasimhan M, Vert G, Bednarek SY, Friml J

Functional Network Mapping Reveals State-Dependent Response to IGF1 Treatment in Rett Syndrome.

Keogh C, Pini G, Gemo I, Kaufmann WE, Tropea D

Long QT interval in Rett syndrome: expanding the knowledge of a poorly understood phenomenon.

Kaufmann WE

Autism Spectrum Disorder Versus Autism Spectrum Disorders: Terminology, Concepts, and Clinical Practice.

Oberman LM, Kaufmann WE

A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study.

Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, Kaufmann WE, Missling CU, Afshar M

Metabolic Signatures Differentiate Rett Syndrome From Unaffected Siblings.

Neul JL, Skinner SA, Annese F, Lane J, Heydemann P, Jones M, Kaufmann WE, Glaze DG, Percy AK

Evolutionarily unique mechanistic framework of clathrin-mediated endocytosis in plants.

Narasimhan M, Johnson A, Prizak R, Kaufmann WA, Tan S, Casillas-PĂŠrez B, Friml J

ANAVEXÂŽ2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome.

Kaufmann WE, Sprouse J, Rebowe N, Hanania T, Klamer D, Missling CU